Menu

Healthtech

Apollo Hospitals Boosts Digital Oncology with Acquisition

Apollo Hospitals Boosts Digital Oncology with Acquisition

Apollo Hospitals Boosts Digital Oncology with Acquisition

With the strategic acquisition of cancer care platform Onco, Apollo Hospitals deepens its digital healthcare capabilities as it gears up for the demerger of Apollo HealthCo.

Summary:
Apollo Hospitals has quietly acquired healthtech startup Onco, which is backed by marquee investors like Accel and Rainmatter. While the financial terms remain undisclosed, sources confirm that the deal was closed in December 2024. This acquisition reinforces Apollo’s growing focus on digital healthcare and cancer care, especially as it prepares for the demerger of its pharmacy and digital platform arm, Apollo HealthCo.

Apollo Hospitals Expands Its Digital Health Footprint
India’s healthcare giant, Apollo Hospitals, has taken a strategic step forward in its digital transformation journey with the acquisition of Onco, a healthtech startup that offers end-to-end cancer care services. While the financial details of the transaction have not been officially disclosed, sources close to the matter revealed that the deal was completed in December 2024.
The acquisition marks a significant milestone in Apollo’s plan to strengthen its digital healthcare capabilities, particularly in oncology, a field that continues to see rising demand and innovation.

About Onco: Empowering Personalised Cancer Care
Founded in 2016 by Dr. Amit Jotwani, an oncologist, and Siddhartha Jain, a former VC and entrepreneur, Onco.com was designed to simplify and democratize cancer treatment by providing patients with access to expert advice, personalised treatment plans, and coordinated care services.
Over the years, Onco has built a robust ecosystem that includes:
– A virtual tumour board to provide multi-disciplinary opinions
– A care management team that supports patients throughout their treatment
– A service that links patients to oncologists, medical facilities, and diagnostic laboratories.
The platform has served over 100,000 cancer patients across India and abroad, becoming a go-to resource for people looking for trusted and comprehensive cancer support. Its services span various stages of cancer, from diagnosis and treatment to post-treatment care and second opinions.

Backed by Prominent Investors
Onco has secured more than $13 million from prominent investors, including:
– Accel (a leading early-stage VC firm)
– Rainmatter Capital (backed by Zerodha)
– Vijay Shekhar Sharma, founder of Paytm
– Alteria Capital
– Prime Venture Partners
These funds helped Onco build its core technology platform, expand its team of oncologists and care managers, and build a data-rich oncology ecosystem.

Why Apollo’s Acquisition Makes Strategic Sense
The acquisition of Onco aligns perfectly with Apollo’s broader vision to dominate the digital health ecosystem. Apollo has been increasingly investing in technology, AI-driven diagnostics, telemedicine, and remote monitoring as part of its digital-first strategy.
Here’s why the Onco acquisition is a perfect strategic fit:
1. Deep Oncology Expertise: Apollo already has a strong presence in cancer treatment with its Apollo Cancer Centres. Onco adds a tech-driven layer that makes cancer care more accessible, affordable, and efficient.
2. Patient-Centric Digital Model: Onco’s platform-centric approach complements Apollo’s digital strategy to provide end-to-end patient journeys — from consultation and diagnosis to treatment and recovery.
3. Data-Driven Insights: With Onco’s oncology-focused patient data, Apollo can now enhance clinical decision-making and personalised treatment through AI and predictive analytics.
4. Synergy with Apollo HealthCo: The acquisition happens at a vital moment as Apollo works on spinning off Apollo HealthCo, its pharmacy distribution and digital health division, into a separate entity.

Apollo HealthCo Demerger in Focus
Apollo Hospitals has been streamlining its operations and sharpening its focus on vertical-specific growth. One of the biggest transformations in progress is the demerger of Apollo HealthCo, which combines its:
-Offline & digital pharmacy operations
-Digital consultation platform (Apollo 24|7)
-Telemedicine and diagnostics
The newly formed entity will focus on tech-enabled omnichannel healthcare services and is expected to attract its investor base. Acquisitions like Onco add significant value to HealthCo’s offerings, enhancing its clinical depth, patient experience, and platform scalability.

Rising Demand for Oncology Solutions
Cancer cases in India are expected to increase greatly, with the Indian Council of Medical Research (ICMR) projecting more than 1.5 million new cases each year by 2025. Limited access to high-quality care in Tier 2 and Tier 3 cities has driven the need for digital oncology solutions like Onco.
By integrating Onco into its ecosystem, Apollo Hospitals can now offer remote cancer consultations, personalised care plans, and cross-speciality collaboration at scale — a critical value proposition for India’s growing cancer burden.

What This Means for the Healthcare Sector
The Apollo-Onco deal signals a growing trend where large hospital chains are acquiring niche healthtech startups to accelerate innovation, improve service delivery, and reach new markets. As the lines between physical and digital healthcare continue to blur, such mergers will become more common.
Startups with deep specialisation in one vertical (like cancer, fertility, mental health, or chronic disease) are becoming prime acquisition targets for larger healthcare conglomerates looking to quickly expand their capabilities.

Future Outlook
With this acquisition, Apollo Hospitals is poised to strengthen its leadership in the oncology space while driving forward its digital health mission. It also sets the stage for Apollo HealthCo to emerge as a tech-powered, patient-first healthcare platform that can potentially list independently or attract strategic investors shortly.
The integration of Onco will likely fuel innovation in care delivery, improve patient navigation in complex cases, and contribute to building India’s most comprehensive and tech-savvy oncology network.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The image added is for representation purposes only

Tata Sons Strengthens Hold on Tata Capital: Shaping the Future of India’s Banking and Financial Sector

L&T Launches India's First ESG Bonds, Raises ₹500 Crore!

L&T’s ₹500 Crore ESG Bond Issue to Power Sustainability

L&T’s ₹500 Crore ESG Bond Issue to Power Sustainability

New Capital Drive to Strengthen

Larsen & Toubro (L\&T), one of India’s top engineering and construction firms, is preparing to raise ₹500 crore by issuing Environmental, Social, and Governance (ESG) bonds — a strategic move that highlights its growing focus on sustainable growth. The funds will be directed toward green and socially responsible projects, reinforcing L\&T’s dedication to long-term ESG goals.

Leveraging ESG-Driven Capital

ESG bonds are a class of debt instruments that enable organizations to attract capital for projects with positive environmental or societal outcomes. Through this ₹500 crore issuance, L\&T aims to tap into a growing base of investors who prioritize responsible investing. The proceeds will be deployed across projects that adhere to ESG principles, covering areas such as renewable energy, sustainable infrastructure, and improved energy efficiency.

Building on Past Sustainability Efforts

This bond offering adds to L\&T’s already solid track record of integrating ESG into its financial strategy. The company had previously secured notable sustainability-linked loans: a \$107 million facility with Sumitomo Mitsui Banking Corporation and a \$150 million loan with Bank of America, which L\&T transitioned into a sustainability-linked loan. These financial arrangements tie the loan terms to measurable sustainability targets, such as lowering greenhouse gas emissions and reducing water usage intensity.

Deepening Investments in Green Ventures

Recently, the company approved an investment of ₹506 crore into L\&T Energy Green Tech Limited, a subsidiary dedicated to renewable energy. This initiative aims to consolidate and expand L\&T’s presence in clean energy markets, including the development of green hydrogen infrastructure and associated value chains.

Scaling Up Renewable Energy Projects

Further demonstrating its green credentials, L\&T has secured large contracts in the Middle East to build two massive solar photovoltaic plants with a combined capacity of 3.5 gigawatts. Valued between ₹10,000 crore and ₹15,000 crore, these projects significantly enhance L\&T’s international renewable energy portfolio and position the company as a major player in global solar power construction.

In Line with Broader Sustainability Trends

L\&T’s push for ESG financing aligns well with both national and global trends. The Reserve Bank of India (RBI) has recognized the importance of green bonds in helping Indian corporations raise funds for sustainability-focused initiatives. L\&T’s ESG bond issuance thus contributes to a broader effort to channel capital into green and socially responsible enterprises, in line with India’s climate action commitments and global environmental goals.

Summary:

Larsen & Toubro’s plan to raise ₹500 crore via ESG bonds marks a strong step toward reinforcing its environmental and social commitments. The funds will fuel a range of sustainability-driven projects, further advancing the company’s position as a responsible corporate leader. Combined with previous sustainability-linked loans and ongoing investments in renewable energy, this new ESG-focused capital drive will help L\&T contribute meaningfully to India’s — and the world’s — sustainable future.

 

 

 

 

 

 

 

 

 

 

 

 

The image added is for representation purposes only

Cognizant Secures $1B Deal with Top Healthcare Firm!

Cognizant Secures $1B Deal with Top Healthcare Firm!

Cognizant Secures $1B Deal with Top Healthcare Firm!

Cognizant Secures $1B Deal with Top Healthcare Firm!

Cognizant has reportedly secured a major $1 billion contract, likely extending its long-term collaboration with UnitedHealth Group, highlighting its extensive expertise in the healthcare IT sector.

Summary:
Cognizant has reportedly secured a $1 billion deal from a prominent US-based healthcare company, with insiders pointing to UnitedHealth Group as the likely client. The multi-year deal is seen as a reaffirmation of Cognizant’s strategic focus on healthcare technology at a time when global IT firms are navigating margin pressures and heightened competition. The agreement highlights Cognizant’s continued strength in healthcare and its growing relevance in delivering AI-driven digital transformation solutions.

Cognizant Bags $1 Billion Deal from US Healthcare Major, Likely UnitedHealth Group
New Delhi, June 2025 – Global IT services and consulting firm Cognizant Technology Solutions has reportedly won a $1 billion deal from a major US-based healthcare company, according to people familiar with the development. While the company has not officially disclosed the client’s identity, multiple analysts and sources have pointed toward a likely renewal or expansion of its engagement with UnitedHealth Group (UHG), one of the biggest health insurance companies in the United States.
This deal, believed to span several years, represents a critical win for Cognizant as it seeks to stabilize and strengthen its revenue base in a highly competitive and rapidly evolving digital transformation market.

A Strategic Comeback in Healthcare IT
Cognizant has long had a strategic focus on the healthcare vertical, contributing nearly one-third of its total global revenue. A renewed billion-dollar deal from a healthcare behemoth such as UHG not only underscores the company’s deep expertise in payer-provider IT solutions but also signals client confidence in Cognizant’s ability to deliver scalable, AI-integrated platforms across domains such as claims processing, electronic health records (EHR), and patient data security.
The development is being viewed as a positive signal to investors and analysts, especially after a series of client losses and executive exits over the past couple of years that had raised concerns about Cognizant’s long-term positioning.

What the Deal Likely Entails
While details of the deal remain confidential, industry watchers speculate that the engagement includes:
Modernization of legacy healthcare systems
AI and machine learning integration for claims analytics and fraud detection
Expansion of cloud-based platforms for scalable healthcare solutions
Enhanced data governance and cybersecurity services
Support for regulatory compliance and interoperability initiatives, including HL7 and FHIR standards
This comes at a time when healthcare companies in the US are accelerating their digital journeys in the wake of increased regulatory scrutiny, data breaches, and patient expectations for better digital engagement.

Analyst View: A Turnaround Moment
According to analysts tracking the IT services sector, this $1 billion deal could be a turning point for Cognizant. Over the past two years, the company has been working to regain lost ground amid rising competition from Infosys, TCS, Accenture, and newer digital-native firms.
“This win shows that Cognizant is still a force to reckon with in the healthcare domain. The size and scope of the deal reaffirm client trust and may help the company recover market share lost in recent years,” said an IT services analyst at a leading brokerage firm.
The deal could also support double-digit growth in the healthcare vertical over the next few years and help improve margins through managed services and automation.

CEO’s Strategic Repositioning
Ever since Cognizant CEO Ravi Kumar S. took charge, the company has been undergoing an internal transformation, with a focus on AI-led delivery models, cloud-first strategies, and decentralized decision-making. This deal validates those efforts and reflects the growing alignment between Cognizant’s capabilities and client needs in the digital era.
Under Ravi Kumar’s leadership, the firm has also made strategic acquisitions to bolster its cloud, data engineering, and healthcare consulting practices, indicating that the billion-dollar deal is not just a financial win but also a validation of Cognizant’s reshaped value proposition.

UHG-Cognizant: A Long-standing Relationship
UnitedHealth Group, the likely client behind this deal, has been associated with Cognizant for more than a decade. In previous years, the companies have collaborated on initiatives involving IT infrastructure, digital claims processing, and consumer engagement platforms.
A renewal of this engagement at such a significant scale not only reflects operational trust but also shows a preference for continuity and domain specialization over switching vendors. It is also indicative of the growing complexity of healthcare IT systems that require strategic partners rather than transactional vendors.

Competitive Landscape and What Lies Ahead
This win comes in the backdrop of increasing competition within the healthcare IT services segment, which has witnessed strong deal activity from players like TCS (with CVS Health), Infosys (with Cigna), and Accenture (with Kaiser Permanente).
By clinching this deal, Cognizant has not only secured a robust revenue pipeline but also signaled its intent to remain at the forefront of healthcare innovation, especially as Generative AI, predictive analytics, and hyper-personalized healthcare solutions become key differentiators in the space.

Conclusion: Reaffirmation of Trust and Transformation Potential
The $1 billion deal is a clear reaffirmation of Cognizant’s ability to deliver high-impact, enterprise-scale solutions for healthcare clients navigating regulatory pressure, digital disruption, and rising costs. It also reestablishes the company as a trusted transformation partner with deep domain knowledge and execution capabilities.
With this, Cognizant gains not just a financial edge but a strategic uplift, positioning itself as a leader in healthcare technology modernization in North America and beyond.

 

 

 

 

 

 

 

 

 

 

 

 

 

The image added is for representation purposes only

Festo Launches ₹500 Crore Facility to Boost Automation

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

 

From coding education to cancer care, Karan Bajaj’s new venture aims to transform oncology outcomes through tech-enabled, personalized lifestyle coaching.

A New Chapter: From Edtech to Healthtech

Karan Bajaj, renowned for founding WhiteHat Jr-a platform that taught coding to children and was acquired by BYJU’S for $300 million in 2020-has shifted his entrepreneurial focus from education to healthcare. His latest venture, Complement1, is based in the United States and targets a critical gap in cancer care: the integration of evidence-based lifestyle interventions into the treatment and recovery process.
After his exit from BYJU’S in 2021 and a period of personal reflection, Bajaj returned to the startup scene with a mission to address the unmet needs of cancer patients, survivors, and those at high risk. Complement1 combines advanced technology, evidence-based clinical practices, and personalized coaching to deliver impactful and enduring benefits for patients.

Complement1: The Vision and Model
Personalized, Daily Support:
Complement1 offers individualized daily support to cancer patients and those at high risk through personalized sessions led by dedicated CoActive Coaches.
These coaches help users incorporate clinically recommended practices in nutrition, physical activity, sleep, and stress management-areas often overlooked in conventional cancer care.

Tech-Enabled, Clinically Validated:

The platform leverages an AI-driven personalization engine to tailor interventions and education for each user. Complement1’s approach is backed by clinical studies, showing outcomes such as a 37% reduction in treatment-related side effects, an 18% decrease in pain levels, and a 27% improvement in sleep quality for its members.
The program boasts over 90% adherence rates, a testament to its daily engagement strategy.
Integration with Healthcare Ecosystem:
Complement1 partners with cancer centers, health plans, and employers to make its platform available to a wider population. Early actuarial modeling suggests that its approach can reduce healthcare costs for cancer patients by up to 30%, benefiting not just individuals but also providers and insurers.

Funding and Growth Plans

Complement1 has secured $16 million in seed funding, led by Owl Ventures and Blume Ventures, along with support from unnamed investors. The funding will be directed toward:
• Expanding the company’s coaching capabilities and operational presence across the U.S.
• Developing its AI-powered personalization platform further
• Improving the digital interface for both users and coaching staff
• Building strategic collaborations with hospitals, insurance providers, and corporate partners
Amit A. Patel, Managing Director at Owl Ventures, commended Complement1 for its unique blend of advanced technology and personalized coaching, calling it a “game-changing approach to transforming cancer care outcomes worldwide.”

The Rise of Second-Time Founders

Bajaj’s journey reflects a growing trend in the Indian and global startup ecosystem, successful founders returning with new, often more ambitious ventures. After high-profile exits, many leaders are leveraging their experience and networks to tackle complex problems in sectors like healthtech, fintech, and sustainability. Bajaj’s shift from edtech to healthtech reflects a broader trend of adaptability and evolving vision among seasoned entrepreneurs.

Lessons from WhiteHat Jr

WhiteHat Jr’s meteoric rise and subsequent controversies-including aggressive marketing, regulatory scrutiny, and eventual shutdown-have shaped Bajaj’s approach to Complement1. This time, the emphasis is on clinical validation, compassionate engagement, and measurable impact. The startup’s initial outcomes and backing from investors indicate a promising base for long-term, scalable expansion.

Conclusion

Karan Bajaj’s Complement1 is poised to make a significant impact on cancer care by addressing the critical, yet often neglected, role of lifestyle interventions in treatment and recovery. With robust funding, a clinically validated approach, and a focus on personalized, tech-enabled coaching, Complement1 is set to redefine support for cancer patients and high-risk individuals. The venture not only marks Bajaj’s successful transition from edtech to healthtech but also signals a broader shift towards holistic, patient-centered care in the digital age.

 

 

 

 

 

 

The image added is for representation purposes only

BEL Sees Stock Rally After Akashteer Demonstration